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Abstract
Background: The aim of our work was to develop and 
validate a reliable LC-MS/MS-based measurement proce-
dure for the quantification of vancomycin in serum, to be 
applied in the context of efforts to standardize and harmo-
nize therapeutic drug monitoring of this compound using 
routine assays.
Methods: Sample preparation was based on protein pre-
cipitation followed by ultrafiltration. In order to minimize 
differential modulation of ionization by matrix constitu-
ents extended chromatographic separation was applied 
leading to a retention time of 9.8  min for the analyte. 
Measurement was done by HPLC-ESI-MS/MS. For internal 
standardization the derivative vancomycin-glycin (ISTD) 
prepared by chemical synthesis was used, HPLC condi-
tions ensured coelution of ISTD with the analyte.
Results: In a bi-center validation total CVs of  < 4% were 
observed for quality control material ranging from 
5.3 mg/L to 79.4 mg/L; accuracy was  ± 4%. No relevant ion 
suppression was observed. Comparative measurement of 
aliquots from 70 samples at the two validation sites dem-
onstrated close agreement.
Conclusions: Employing a closely related homologue 
molecule for internal standardization and the use of MS/
MS following highly efficient sample pre-fractionation by 
HPLC, the method described here can be considered to 
offer the highest level of analytical reliability realized so 
far for the quantification of vancomycin in human serum. 
Thus, the method is suitable to be used in a comprehen-
sive reference measurement system for vancomycin.
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Introduction
The glycopeptide compound vancomycin is one of the 
most widely used antimicrobial agents for the treatment 
of serious gram-positive infections including methicillin-
resistant Staphylococcus aureus (MRSA) [1]. Vancomycin is 
also among the highest volume target analytes in thera-
peutic drug monitoring (TDM) for many years now [1–3]. 
TDM of vancomycin mainly aims to balance therapeutic 
efficacy against the risk of nephrotoxicity. It has been 
shown in several studies – applying various analytical 
methods – that high vancomycin trough levels are asso-
ciated with the incidence and extend of nephrotoxicity 
[4, 5]. However, low trough levels of vancomycin may lead 
to increased occurrence of resistant strains of S. aureus 
and failure of treatment in complicated infections. Based 
on these issues the American Society of Health-System 
Pharmacists, the Infectious Diseases Society of America, 
and the Society of Infectious Diseases Pharmacists have 
published expert panel recommendations for vancomycin 
TDM, recommending trough serum concentrations of van-
comycin of 15–20 mg/L in complicated infections [1].
These recommendations, however, do not take into 
consideration that routine serum vancomycin quanti-
fication by commercial immunoassays is still lacking 
between-method standardization and substantial method 
bias can be found [6]. In the proficiency testing scheme of 
the German Association of Clinical Chemistry and Labo-
ratory Medicine [DGKL; Referenzinstitut für Bioanalytik 
(RfB), Bonn, Germany] at present 14 tests are monitored. 
The bias between the lowest reading vancomycin test 
and the highest reading test is continuously found in the 
range of 40% in this external quality assessment program. 
Considering the clear-cut vancomycin target concentra-
tion ranges, it is likely that different clinical dosing deci-
sions are made today in a substantial number of patients 
depending on the assay which is used in an individual 
institution. Notably, these consensus target concentra-
tions ranges cannot be traced back conclusively to a 
defined analytical method.
From these considerations it has to be concluded that 
improved harmonization and standardization of serum 
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vancomycin measurement is warranted. A future compre-
hensive reference measurement system for vancomycin 
measurement has to include, on the one hand, reliable 
reference materials, but on the other hand, a robust and 
reliable method for the specification of working calibration 
materials, and proficiency testing materials, as well as for 
the evaluation of routine immunometric tests referring to 
large reference serum panels. The aim of our work was to 
develop and to validate such a candidate reference method.
Due to the rather high molecular weight and the 
limited thermal stability of vancomycin, LC-MS/MS was 
the most promising technology for this aim. Indeed, 
several LC-MS/MS methods for the quantification of 
serum vancomycin concentrations have been described 
previously [7–9]. These methods, however, rely on inter-
nal standard compounds with are structurally not related 
to the target analyze (teicoplanin, atenolol).
LC-MS/MS-based reference methods [10] usually 
involve stable isotope labeled compounds for internal 
standardization. Since vancomycin is a bio-product, pro-
duction of a respective material is hardly possible. Conse-
quently we designed a suited internal standard compound 
by stable chemical derivatization of vancomycin which 
showed almost identical behavior during sample prepa-
ration and HPLC-MS/MS separation. The molecule was 
modified only marginal by introduction of a small func-
tional group not changing the polarity of the molecule 
leading to a different molecular mass.
The intended use of this method protocol described 
herein is the specification of serum-based samples within 
the calibration range of the method in both an industrial 
and research setting. Consequently, high sample through-
put did not have major priority in the development of this 
method, while robustness and reproducibility in differ-
ent instrument settings was an essential goal. Thus, we 
decided to apply highly efficient chromatographic frac-
tionation in order to minimize matrix effects, and to apply 
an innovative bi-centric validation protocol.
Materials and methods
Chemicals and reagents
Vancomycin-hydrochloride pure substance was purchased as a USP 
reference standard from U.S. Pharmacopeia (USP Rockville MD, USA; 
LOT M0H006; CAS 1404–93–9; molecular weight 1485.71; molecular 
formula C66H75Cl2N9O24.HCl; vials containing 99,300 µg vancomycin 
activity; Figure 1A). USP-based routine human serum calibrators for 
immunoassays (Cal A, 5 mg/L; Cal B, 40 mg/L; Cal C, 80 mg/L) were 
purchased from Roche Diagnostics (Mannheim, Germany). The latter 




Figure 1 Synthesis of vancomycin-glycine.  
(A) Vancomycin (molecular weight: 1449.25; molecular formula: 
C66H75Cl2N9O24). The only carbon acid function accessible for forma-
tion of an ester derivative is indicated. (B) Peptide coupling of van-
comycin to vancomycin-glycine-methyl ester. (C) Saponi fication of 
vancomycin-glycine-methyl ester to vancomycin-glycine (molecular 
weight: 1506.34; molecular formula: C68H78Cl2N10O25).
Methanol and water (both HPLC-grade) for chromatography 
were from J.T. Baker (Griesheim, Germany). Formic acid and trichlo-
roacetic acid were from Merck (Darmstadt, Germany).
For synthesis of a derivative of vancomycin to be used as an 
internal standard, vancomycin-hydrochloride and glycine methyl 
ester hydrochloride were purchased from Sigma-Aldrich (Steinheim, 
Germany). O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hex-
afluorophosphate (HBTU), Dimethyl sulfoxide (DMSO), N,N-Dimeth-
ylformamide (DMF), diisopropylethylamine, acetic acid, sodium car-
bonate, water and acetonitrile were from J.T. Baker.
Synthesis of vancomycin-glycine
Peptide coupling
Vancomycin-hydrochloride (200 mg; 135 µmol), glycine methyl ester 
hydrochloride (33.8 mg; 269 µmol) and HBTU (76.5 mg; 202 µmol) 
were dissolved in DMSO (2 mL) and DMF (0.66 mL). The resulting 
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solution was cooled to 0°C, and diisopropylethylamine (117 µL; 
673  µmol) was added. After stirring at room temperature for 2.5 h, 
the mixture was diluted by acetic acid (0.5 mL), water (2 mL) and ace-
tonitrile (0.5 mL). Using preparative reverse phase HPLC (C18; Vydac 
218TP152050; 5 × 25 cm) the reaction product vancomycin-glycine-
methyl ester (Vancomycin-Gly-OMe; Figure 1B) was purified and sub-
sequently dried to a white powder (approx. 150 mg).
Saponification of vancomycin-glycine-methyl ester
Vancomycin-Gly-OMe (75 mg; 49.3 µmol) was added to sodium car-
bonate buffer (2%; 5 mL; pH 10.0) at room temperature. The reac-
tion mixture was stirred for 6 h and then acidified with acetic acid 
(0.5 mL). The main reaction product vancomycin-glycine (Figure 1C) 
was again purified by preparative reverse phase HPLC. After drying a 
white powder was obtained.
For preparative HPLC separation, a Dionex P580P HPG HPLC 
Binary High-pressure Gradient Pump (Thermo Scientific,  Sunnyvale, 
USA), a Rheodyne switching valve (IDEX, Rohnert Park, USA), a 
Gynkotek SP-6 detector (Thermo Scientific) and a LKB 2211 Superrac 
fraction collector (AIE, Haverhill, USA) were used. As column a  Vydac 
C 18 (218TP152050; 5 × 25 cm) (Grace, Worms, Germany) was used. 
The mobile phase consisted of Eluent A [aqueous trifluoroacetic acid 
(0.1% v/v)] and Eluent B [80% acetonitrile/20% water containing tri-
fluoroacetic acid (0.1% v/v)], delivered with a flow rate of 35 mL/min 
during a run time of 120 min. The gradient elution program was as 
follows: 100% eluent A for 100 min; increase to 25% eluent B over 
3 min, afterwards an increase up to 100% eluent B hold for 7 min. 
Separation was monitored at 226 nm. The uniform peak fraction elut-
ing around 70 min was collected (Figure 2). The solvent was removed 
under low pressure and the residue was brought to dryness under 
vacuum to obtain approximately 40 mg of a white solid.
The final product of this procedure was analyzed by  ESI-TOF-MS 
in the positive mode; this offered the following fragmentation 
 patterns: m/z 1507 (M+H); 1364 [(Vanc-143)+]; 754 [(M+2H)2+], which 
is evidentiary for Vancomycin-Gly; (Vanc-143)+ corresponds to the 
loss of the 4-amino-4-methyl-5-hydroxy-6-methyl-glucose residue 
( Figure 1A). Since the molecular structure of the vancomycin mole-
cule offers only one carboxylic acid function which is available for 
reaction to an ester (Figure 1A), such uniform molecular structure of 
vancomycin-glycine can be expected.
Preparation of stock solutions, calibrators 
and quality control samples
The dry pure substance of vancomycin weighted into vials by USP 
was dissolved in 100  mL of HPLC-grade water according USP han-
dling instructions, leading to a stock solution containing 993 mg/L 
vancomycin based on USP certificate. An internal standard working 
solution (5 mg/L) was prepared by dissolving vancomycin-glycine in 
HPLC-grade water.
Drug-free human serum was spiked with vancomycin stock solu-
tion to yield the following five calibrator concentrations: 1.06 mg/L; 
21.1 mg/L; 42.2 mg/L; 63.3 mg/L; and 84.4 mg/L. Calibrator 0 was 
drug free human serum. Calibrator samples were stored at −20°C, the 
internal standard solution at +4°C during the study.
Quality control samples (QC) in five concentration levels were 
prepared. QC 1–3 were mixtures of left-over patients’ samples found 
in different concentration ranges in routine analyses (for QC 1, sam-
ples between 1 and 9 mg/L; for QC 2, samples between 9 and 13 
mg/L; and for QC 3 samples  > 13 mg/L). QCs 1–3 were used to assess 
the reproducibility of the method. QC 4 and QC 5 were prepared by 
spiking drug-free human serum with a vancomycin working solu-
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Figure 2 Preparative chromatography applied to isolate vancomycin-glycine eluting after approximately 70 min.
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vancomycin solution was prepared separately from the solution used 
for the preparation of calibrator samples. All QC samples were ali-
quoted and stored at −20°C until analysis on either validation site.
High-performance liquid chromatography 
conditions
At laboratory site 1 (Munich) a Waters Alliance 2795, at site 2 
( Penzberg) a Waters Acquity LC system was used. As analytical 
 column a Fortis C8 (100 mm × 2.1 mm, 3 µm) (dichrom GmbH, Marl, 
Germany) was used. The column temperature was 40°C. The injection 
volume was 20 µL. The mobile phase consisted of two solvents;  Eluent 
A: aqueous  formic acid (0.1% v/v); Eluent B: methanol containing 
0.1% formic acid (0.1% v/v). Run time was 21 min with a flow rate of 
0.3 mL/min and an  gradient elution program as follows: 100% A for 
3 min; linear increase to 30% B over 7 min, hold for 2 min;  afterwards 
a linear increase up to 80% B within 1 min, hold for 2 min; return to 
the initial condition within 1 min and re-equilibration for 5 min. Via 
a post-column switching valve, the HPLC eluate was directed into the 
mass spectrometer between 4.0 and 10.5 min after injection; during 
the residual run time the eluent was diverged into waste.
Mass spectrometric conditions
Mass spectrometric analysis was performed using Waters Quattro 
 Micro instruments in the positive ionization mode on both laboratory 
sites. The following settings were applied: Capillary voltage, 3.2  kV; 
cone voltage, 20.0 V; collision energy, 12 eV; source temperature, 
120°C; and desolvation temperature 480°C. The dwell time was 0.2 ms; 
inter-channel delay, 0.02 ms; and inter-scan delay 0.02 ms. Mass spec-
trometric data were acquired from 4.5 to 12.0 min after injection.
A collision-induced product ion scan of vancomycin is shown in 
Figure 3. For vancomycin the mass transition 725 > 1306 was recorded, 
and for vancomycin-glycine 753 > 1362. This corresponds to the dou-
bly charged protonated molecules as the precursor ions, and singly 
charged fragments as the product ions – leading to higher m/z values 
of the product ions compared to the precursor ions. Mass resolution 
was tuned to obtain a mass signal width of 1 Da at 50% height of the 
product ion signal.
Sample preparation
Seventy-five µL of internal standard working solution and 75 µL of the 
calibrator sample or of unknown serum sample were pipetted into 
1.5  mL polypropylene microcentrifuge tubes. For equilibration the 
solution was shaken at room temperature for 30 min. Subsequently, 
300 µL of trichloroacetic acid (15%) were added. Protein precipita-
tion was achieved by shaking at room temperature for 5 min. The 
tubes were centrifuged at 14,000 g for 10 min. The clear supernatant 
was pipetted into Amicon Ultra-0.5 mL 10k ultra-filtration devices – 
(Millipore, Billerica, USA; 10,000 nominal molecular weight cut-off). 
The devices were placed into a centrifuge and filtration was achieved 
by centrifugal force for 45 min at 7000 g. The filtrate (approx. 450 µL) 
was transferred into HPLC vials with small-volume inserts.
Five-point calibration was applied in a concentration range 
from 1.06 to 84.4 mg/L. For quantification the Waters QuanLynx soft-
m/z










Figure 3 Production scan of two-fold charged vancomycin.
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ware module was used with the following setting: Polynome type, 
linear; origin, include; weighting function, 1/x; axis transformation, 
none; smoothing method, mean; smoothing width, 1; smoothing it-
erations, 1.
Method validation
The method was validated in a bi-centric protocol: Institute of Labo-
ratory Medicine, Hospital of the University of Munich, Germany, site 
1; and Roche Diagnostics, Penzberg, Germany, site 2.
Prior to each analytical run, a system suitability screening test 
was performed; for this the preparation of calibrator 1 (1 µg/mL) was 
injected. A signal-to-noise ratio of  > 10:1 for the MRM-trace of vanco-
mycin was defined as mandatory for a subsequent analytical run.
In order to test the specificity of the method, 10 leftover clinical 
serum samples from intensive care patients not treated with vanco-
mycin were used. These samples were processed and analyzed with-
out addition of the internal standard solution in order to verify the 
absence of peaks within the retention time window of the analyte or 
the internal standard, respectively.
In order to characterize the potential impact of residues of the 
sample matrix on the ionization of analyte and internal standard, 
two investigations were performed. In the post-column-infusion set-
ting [11], a pure solution of vancomycin (1 mg/L) was infused with a 
syringe pump at constant rate using a T-piece into the column efflu-
ent, in order to generate a MS/MS background signal. Upon injection 
of processed serum samples, potential modulation of the background 
signal was monitored. In a second experiment, extracted serum from 
three patients not treated with vancomycin was spiked with a solu-
tion of vancomycin to a concentration of 21 mg/L each. For compari-
son, a neat sample in water was spiked in the same way in triplicate. 
Both sets of samples were analyzed with the MS/MS method and 
peak areas were recorded in order to estimate potential effects of the 
serum-derived sample matrix on ionization of vancomycin, as matrix 
effect (%) according to Matuszewski et al. [12].
Accuracy of the method was tested by analyzing three external 
reference calibrator samples (USP Calibrators, Roche) and the qual-
ity control samples QC 4 and QC 5 which were prepared on valida-
tion site 2. Each sample was analyzed in triplicate on both validation 
sites.
Imprecision of the method was studied by analyzing aliquots of 
the QC samples 1–5 in two series of six-fold determination on both 
study sites, leading to a total of 24 results for each sample.
To roughly characterize a lower limit of detection and the per-
formance of the method implementation in a concentration range be-
low the lowest calibrator sample, a spiked sample with a vancomycin 
concentration of 0.1 µg/mL was injected in triplicate on both study 
sites and the signal-to-noise ratio was assessed.
In order to test the stability of processed samples, extracts of 
three patients’ samples were stored at +8°C and −20°C. These sam-
ples were re-quantified in analytical series after 1 day, 2 days, and 
1 week. These results were compared with the results found in the 
initial analytical run.
Left-over serum from 70 patients’ samples send to the Institute 
of Laboratory Medicine for clinically indicated vancomycin measure-
ment were used to study the agreement between analyses performed 
with the described LC-MS/MS method on both validation sites. The 
samples were recruited consecutively without any selection, thus re-
flecting the typical distribution of concentrations found in a tertiary 
care hospital. After anonymization, two aliquots of these samples 
were prepared and stored at −20°C until analysis on either study site 
within 4 weeks. This procedure was approved by the Institutional 
Review Board.
Results
A representative LC-MS/MS chromatogram is shown in 
Figure 4. Analyte and the internal standard compound 
vancomycin-glycine co-eluted as requested. Fifty MS/
MS-data points were acquired over both chromato-
graphic peaks. Minor signals from isobaric compounds 
were observed eluting slightly beforehand and follow-
ing the peaks. Their pattern was found constant in both 
calibrator samples and patients’ samples on both study 
sites, and peak integration was performed consistently. 
The pattern did not change with the storage time of 
samples.
In all analytical series the regression coefficient r2 
was  ≥  0.99 for all calibration runs over the concentration 
range from 1.06 to 84.41 mg/L. The slope of the calibration 
line was 0.25 ( ± 5%).
The signal-to-noise ratio observed in the system suit-
ability screening test (injection of the lowest calibrator 
sample) was  > 400:1 in all analytical series on study site 1, 
and  > 100:1 on site 2.
The handling of the method was found convenient, 
including the ultrafiltration step. The entire instrumental 
setting was robust throughout the study period on both 
sites, in particular regarding HPLC back-pressure and ion-
ization yield.
The analysis of 10 serum samples from patients which 
were not treated with vancomycin proved the specificity of 
the method; no peak signals in retention time windows of 
vancomycin or vancomycin-glycin were observed.
Figure 5 displays the results of the post-column infu-
sion experiment which was performed to characterize the 
impact of serum-derived sample materials on the ioniza-
tion yield of vancomycin. The figure shows an overlay of 
the signal pattern generated by injection of extract from 
a vancomycin-free sample, and from a patient’s sample. 
During the time period in which the chromatographic 
eluate was transferred to the MS/MS system a con-
stant signal of the continuously infused analyte can be 
observed. There was no obvious drop or increase in ion 
yield at the retention time of vancomycin. In the spiking 
experiment, a matrix effect of –9% according to Matusze-
wski et al. [12] was observed.
Table 1 displays the analytical accuracy realized for 
the analysis of standard and quality control materials; 
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for each single determination a bias of   ≤   ± 4% was 
observed for the five materials investigated on both 
study sites which is within the  ± 3 SD range of the 
method.
The data of the imprecision study are given in 
Table 2. Intra-assay imprecision observed for the five 
samples ranged from 1.1% to 3.9% CV. The total CV observed 
for aliquots of these samples analyzed on both study 
sites (4 series, 24 determinations) ranged from 1.9% to 
3.8%.
In a sample spiked to a vancomycin concentration of 
0.1 mg/L, a mean signal-to-noise ratio from three injec-
tions of 52:1 (site 1) and 14:1 (site 2) was observed.
Stability of processed samples (autosampler on board 
stability) is shown in Table 3; sample extracts were found 
to be stable for at least 1 week at +8°C with bias of  ≤  ± 3% 
compared to initial measurement.
For 70 unselected left-over serum samples which 
were analyzed to study the between-laboratory agree-
ment of the method, mean concentrations of 9.4 mg/L and 
9.9 mg/L were observed on site 1 and site 2, respectively, 
with median concentrations of 8.8 mg/L and 9.6  mg/L 
(Figure 6). Coefficient of variation observed for the inter-
nal standard peak area was 14% on site 1 and 10% on site 2. 
Pearson’s r was 0.99. Linear regression demonstrated the 
following equation:
Figure 4 Representative MS/MS chromatogram of vancomycin (calibrator sample 1, with vancomycin-glycin as the internal standard).
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site 2 = 1.04 * site 1+0.03 (95% confidence interval for 
slope: 1.00–1.09; 95% confidence interval for intercept: 
−0.42 mg/L to 0.49 mg/L)
Discussion
We here report a HPLC-MS/MS method for the quantifica-
tion of the antibiotic compound vancomycin in serum, 
which is intended to be used in the context of standardiza-
tion and harmonization of routine assays for this analyte. 
An essential novelty of the method protocol is the fact that 
an internal standard compound was prepared as a homo-
logue by derivatization of vancomycin to vancomycin-gly-
cin. Compared to previously reported LC-MS/MS methods 
for vancomycin quantification [7–9], the molecular struc-
ture of this internal standard compound is much closer 
related to that of the target analyte and ensures identi-
cal chromatographic behavior in the chosen setup. In 
general, matrix effect on the ionization of analytes is best 
compensated for by the use of stable isotope labeled inter-
nal standard compounds; however, since vancomycin is a 
biological product such labeled compounds are not avail-
able. We conclude that the method for the quantification 
of vancomycin described here has the highest metrologi-
cal level realized so far, suggesting this protocol as a can-
didate reference method.
A bi-centric method validation characterized the 
method as specific, accurate and precise. The between-
laboratory agreement was found acceptable with  < 4% 
bias for the analysis of a large series of authentic clinical 
Time














Figure 5 Post-column infusion experiment to assess matrix effects on the ionization of vancomycin. Overlay of a run with extract from drug-
free serum and of a clinical sample.
Table 1 Analytical accuracy observed for external calibration material (Cal A-C) and quality control material manufactured on study site 2 
(both materials based on USP vancomycin standard).
Target concentration Cal A, 5.0 mg/L Cal B, 40.0 mg/L Cal C, 80.0 mg/L QC 4, 39.7 mg/L QC 5, 79.4 mg/L
Penzberg (n = 3)
 Observed mean conc. 5.1 40.4 79.6 40.1 78.0
 Recovery % 104/100/102 101/100/102 101/99/99 100/101/99 96/98/99
Großhadern (n = 3)
 Observed mean conc. 5.1 40.6 80.4 40.4 81.8
 Recovery % 104/100/104 103/102/100 103/99/100 99/102/103 103/101/103
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sample materials on two study sites. Thus, the perfor-
mance of this method – which is based on a homologue 
for internal standardization – is almost equal to that of 
typical isotope dilution LC-MS/MS methods. Control of 
matrix effects was verified by post-column-infusion and 
spiking experiments.
Minor isobaric interference was observed in the 
MS/MS chromatograms of analyte and internal standard 
(Figure  4); the nature of the respective compounds has 
not been disclosed. Efficient chromatographic separation 
and consistent peak integration is important for optimum 
reproducibility of analytical series.
The method described here was not optimized regard-
ing a routine use in the clinical laboratory. Extended 
chromatography was applied in order to minimize matrix 



















Figure 6 Between-laboratory comparison of serum vancomycin 
measurement by LC-MS/MS (n = 70; vancomycin in mg/L).
Table 2 Imprecision (coefficient of variation) observed for quality control materials.
QC 1, 5.3 
mg/L
QC 2, 12.4 
mg/L
QC 3, 13.9 
mg/L
QC 4, 39.7 
mg/L





CV % 3.5 1.4 2.6 1.3 1.4
Intra-assay (n = 6)
Day B




CV % 1.5 1.5 1.3 2.1 0.8
Intra-assay (n = 6)
Day B
CV % 1.4 1.1 3.1 2.0 1.6
Pooled data from both study sites
Inter-assay (n = 24)
CV % 2.8 2.2 3.8 1.9 2.2
Table 3 Stability of sample extracts (autosampler stability).
Recovery in % 
Storage
Serum 1 Serum 2 Serum 3
+8°C −20°C +8°C −20°C +8°C −20°C
Penzberg
1 day 102 102 104 101 102 101
2 days 104 109 103 104 104 104
1 week 99 99 98 97 100 98
Großhadern
1 day 96 99 99 95 100 101
2 days 98 97 101 97 99 101
1 week 100 96 103 96 101 101
standard, thereby optimizing the analytical reliability. 
This, however, resulted in a retention time of 9.8 min and 
a total run-time above 20 min. The sample preparation 
protocol is straightforward and based on protein precipi-
tation. Subsequent ultrafiltration was performed in order 
to maximize the stability and robustness of the method.
To date no generally accepted validation protocol 
for quantitative bio-medical analytical methods using 
LC-MS/MS is available. The widely used FDA protocol [13] 
has important limitations and is mainly designed for the 
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validation of pharmacokinetic batch studies in individ-
ual laboratories. However, a prerequisite for a reference 
method is robustness over time and space. Our approach 
of a bi-centric validation can give an impression on the 
general robustness of the method realized in different 
instrument installations and laboratories. We suggest 
such an assessment of between-instrument or between-
laboratory agreement for validation protocols applied for 
clinical mass spectrometry methods, just as it is standard 
in the validation of commercial immunoassays.
We defined a signal-to-noise ratio for the lowest con-
centration calibrator sample which is required as the 
acceptance criterion in a system suitability test. The con-
centration range below the lowest calibrator sample was 
not addressed systematically in the validation study, since 
this would be outside the intended use of the method.
Besides a robust analytical method, the purity of 
standard compounds used is crucial for the implementa-
tion of a reference measurement system for vancomycin in 
the future. Detailed characterization of the primary vanco-
mycin standard has not been addressed in this work. All 
concentrations are based on the USP Pharmacopeia cer-
tificates delivered with the purchased material.
In summary, we were able to describe a robust and 
reliable LC-MS/MS-based measurement procedure for the 
quantification of vancomycin in human serum which may 
be used in the context of a reference measurement system. 
Such a system may contribute to increase the added clini-
cal value of routine vancomycin therapeutic drug moni-
toring which is so far limited by rather poor agreement 
between routine methods.
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